-
1دورية أكاديمية
المؤلفون: G. A. Ignatenko, G. G. Taradin, N. T. Vatutin, I. V. Kanisheva, Г. А. Игнатенко, Г. Г. Тарадин, Н. Т. Ватутин, И. В. Канишева
المصدر: The Russian Archives of Internal Medicine; Том 9, № 5 (2019); 348-366 ; Архивъ внутренней медицины; Том 9, № 5 (2019); 348-366 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-0-5
مصطلحات موضوعية: геморрагические осложнения, venous thromboembolism, thromboembolism of pulmonary artery, treatment, risk stratification, anticoagulant therapy, direct oral anticoagulants, systemic thrombolysis, fibrinolysis, bleeding complications, венозная тромбоэмболия, тромбоэмболия легочной артерии, лечение, стратификация риска, антикоагулянтная терапия, прямые оральные антикоагулянты, системный тромболизис, фибринолиз
وصف الملف: application/pdf
العلاقة: https://www.medarhive.ru/jour/article/view/963/835Test; https://www.medarhive.ru/jour/article/view/963/842Test; Konstantinides S.V., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) endorsed by the european respiratory society (ERS). European Heart Journal. 2014; 35(43): 3033–69, 3069a-3069k. DOI:10.1093/eurheartj/ehu283.; Tritschler T, Kraaijpoel N, Le Gal G, Wells PS. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018 Oct 16;320(15):1583-1594. doi:10.1001/jama.2018.14346.; Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(9): 832.e13-832. doi:10.1016/j.amjmed.2013.02.024; Konstantinides S.V., Barco S., Lankeit M., Meyer G. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90. doi:10.1016/j.jacc.2015.11.061.; Carrier M, Righini M, Wells PS, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications: a systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010;8(8):1716-1722. doi:10.1111/j.1538-7836.2010.03938.x; Ватутин Н.Т., Тарадин Г.Г., Канишева И.В. и др. Роль интервенционных методов в лечении острой легочной эмболии. Архивъ внутренней медицины. 2018; 8(5):346-360. doi:10.20514/22266704-2018-0-5-346-360.; Torbicki A, Perrier A, Konstantinides S, et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008 Sep;29(18):2276-315. doi:10.1093/eurheartj/ehn310.; Jaff M.R., McMurtry M.S., Archer S.L., et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a Scientific Statement from the American Heart Association. Circulation 2011;123(16):1788-830. doi:10.1161/CIR.0b013e318214914f.; Sekhri V, Mehta N, Rawat N, et al. Management of massive and nonmassive pulmonary embolism. Arch Med Sci. 2012 Dec 20; 8(6):957-69. doi:10.5114/aoms.2012.32402.; Bĕlohlavek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013 Spring;18(2):129-38.; Corrigan D, Prucnal C, Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin Exp Emerg Med. 2016 Sep; 3(3): 117–125. doi:10.15441/ceem.16.146; Miller G.A., Sutton G.C., Kerr I.H., et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2:681– 684.; Aujesky D., Obrosky D.S., Stone R.A., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am. J. Respir. Crit. Care Med. 2005;172: 1041–1046.; Jimenez D, Aujesky D, Moores L, et al.; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010 Aug 9;170(15):1383-9. doi:10.1001/archinternmed.2010.199; Huisman M.V., Barco S., Cannegieter S.C., et al. Pulmonary embolism. Nat. Rev. Dis. Primers. 2018 May 17;4:18028. doi:10.1038/nrdp.2018.28.; Kabrhel C., Jaff M.R., Channick R.N., et al. A multidisciplinary pulmonary embolism response team. CHEST Journal. 2013; 144(5):1738-1739.; Root C.W., Dudzinski D.M., Zakhary B., et al. Multidisciplinary approach to the management of pulmonary embolism patients: the pulmonary embolism response team (PERT). J Multidiscip Healthc. 2018 Apr 5;11:187-195. doi:10.2147/JMDH.S151196.; Petriş AO, Konstantinides S, Tint D, et al. Therapeutic advances in emergency cardiology: acute pulmonary embolism. Am J Ther. 2019 Mar/Apr;26(2):e248-e256. doi:10.1097/MJT.0000000000000917.; Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960;275(7138):1309–12.; Jolly M., Phillips J. Pulmonary embolism: current role of catheter treatment options and operative thrombectomy. Surg. Clin. North. Am. 2018 Apr;98(2):279-292. doi:10.1016/j.suc.2017.11.009.; Chopard R, Andarelli JN, Humbert S, et al. Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry. Thromb Res. 2019 Feb;174:27-33. doi:10.1016/j.thromres.2018.12.013.; Stein PD, Dalen JE, Matta F, et al. Optimal therapy for unstable pulmonary embolism. Am J Med. 2019 Feb;132(2):168-171. doi:10.1016/j.amjmed.2018.09.018.; Borohovitz A, Weinberg MD, Weinberg I. Pulmonary embolism: Care standards in 2018. Prog Cardiovasc Dis. 2018 Mar — Apr;60(6):613621. doi:10.1016/j.pcad.2017.12.005.; Hepburn-Brown M, Darvall J, Hammerschlag G. Acute pulmonary embolism: a concise review of diagnosis and management. Intern Med J. 2019 Jan;49(1):15-27. doi:10.1111/imj.14145; Kearon C, AgenoW, Cannegieter SC, et al.; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480-1483. doi:10.1111/jth.13336; Carrier M., Le G.G., Wells P.S., et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann. Intern. Med. 2010 May 4;152(9):578-89. doi:10.7326/0003-4819-152-9201005040-00008.; Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893.; Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.; Heidbuchel H., Verhamme P., Alings M., et al. EHRA practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation: executive summary. Eur Heart J. 2013 Jul; 34(27): 20942106. doi:10.1093/eurheartj/eht134.; Beyer-Westendorf J., Verhamme P., Bauersachs R. Betrixaban for prevention of venous thromboembolism in acute medically ill patients. Eur Heart J Suppl. 2018 May;20(Suppl E):E16-E22. doi:10.1093/eurheartj/suy017; van Es N., Coppens M., Schulman S., et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; Sep 18; 124(12):1968-75. doi:10.1182/blood-2014-04-571232.; van der Hulle T., Kooiman J., den Exter P.L., et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J. Thromb. Haemost. 2014;12(3):320-8. doi:10.1111/jth.12485.; Arcadi FA, Portaro S, Giorgianni R, et al. New versus old oral anticoagulants: how can we set the scale needle? Considerations on a case report. Medicina (Kaunas). 2019 Mar 17;55(3). pii: E71. doi:10.3390/medicina55030071; Dawwas GK, Brown J, Dietrich E, et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2019 Jan;6(1):e20-e28. doi:10.1016/S23523026(18)30191-1.; Schulman S., Kearon C., Kakkar A.K., et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. doi:10.1056/NEJMoa0906598.; Schulman S., Kakkar A.K., Goldhaber S.Z., et al.; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-72. doi:10.1161/CIRCULATIONAHA.113.004450; Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. doi:10.1056/NEJMoa1007903.; Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi:10.1056/NEJMoa1113572; Agnelli G., Buller H.R., Cohen A., et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507.; Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15. doi:10.1056/NEJMoa1306638.; Martin K., Beyer-Westendorf J., Davidson B.L., et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J. Thromb. Haemost. 2016 Jun;14(6):1308-13. doi:10.1111/jth.13323.; Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425-435. doi:10.1182/blood-2018-06-820746; Shakur H, Roberts I, Bautista R, et al.; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5.; Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017 Apr;43(3):277-290. doi:10.1055/s-0036-1597296; Mosarla RC, Vaduganathan M, Qamar A, et al. Anticoagulation strategies in patients with cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Mar 26;73(11):1336-1349. doi:10.1016/j.jacc.2019.01.017; Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10; 349(2):146-53.; Lee AYY, Kamphuisen PW, Meyer G, et al.; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015 Aug 18;314(7):677-686. doi:10.1001/jama.2015.9243.; Raskob GE, van Es N, Verhamme P, et al.; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378:615–24. doi:10.1056/NEJMoa1711948; Young A, Marshall A, Thirlwall J, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D Pilot Trial. Blood 2017; 130:625.; Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res 2018: doi:10.1016/j.thromres.2018.02.144.; Peacock WF, Singer AJ. Reducing the hospital burden associated with the treatment of pulmonary embolism. J Thromb Haemost. 2019 Mar 9. doi:10.1111/jth.14423; Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018 Sep;16(9):1891-1894. doi:10.1111/jth.14219.; Bartel B. Systemic thrombolysis for acute pulmonary embolism. Hosp. Pract. 2015;43(1):22-7. doi:10.1080/21548331.2015.1001302.; Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017 Feb;38(1):56-65. doi:10.1055/s-0036-1597560.; Marti C., John G., Konstantinides S., et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2015; 36(10):605-14. doi:10.1093/eurheartj/ehu218.; Stein P.D., Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med. 2012; 125(5):465-70. doi:10.1016/j.amjmed.2011.10.015.; Murphy E, Lababidi A, Reddy R, et al. The role of thrombolytic therapy for patients with a submassive pulmonary embolism. Cureus. 2018;10(6):e2814. doi:10.7759/cureus.2814; Virk HUH, Chatterjee S, Sardar P, et al. Systemic thrombolysis for pulmonary embolism: evidence, patient selection, and protocols for management. Interv Cardiol Clin. 2018 Jan;7(1):71-80. doi:10.1016/j.iccl.2017.08.001.; Никитина О.В., Михайлов И.П., Кудряшова Н.Е. и др. Тромболитическая и антикоагулянтная терапия при тромбоэмболии легочной артерии: влияние на легочную перфузию (часть 2). Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. 2018; 7(2): 134–143. DOI:10.23934/2223-9022-2018-7-2-134-143.; Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125(3):e82–e86. doi:10.1016/j.thromres.2009.09.017; Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2(3):227-229.; Kline J.A., Steuerwald M.T., Marchick M.R., et al. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009;136:1202-10.; Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18; 311(23):2414-21. doi:10.1001/jama.2014.5990; Bougouin W., Marijon E., Planquette B., et al.; on behalf from the Sudden Death Expertise Center. Pulmonary embolism related sudden cardiac arrest admitted alive at hospital: Management and outcomes. Resuscitation. 2017;115:135-140. doi:10.1016/j.resuscitation.2017.04.019.; Zuin M, Rigatelli G, Carraro M, et al. Systemic thrombolysis in haemodynamically unstable pulmonary embolism: The earlier the better? Thromb Res. 2019 Jan;173:117-123. doi:10.1016/j.thromres.2018.11.029.; Fernandes CJCDS, Jardim CVP, Alves JL Jr, et al. Reperfusion in acute pulmonary thromboembolism. J Bras Pneumol. 2018 Jun 7:0. doi:10.1590/S1806-37562017000000204.; Becattini C., Agnelli G., Lankeit M., et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur. Respir. J. 2016;48(3):780-6. doi:10.1183/13993003.00024-2016.; Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014 Apr;12(4):459-68. doi:10.1111/jth.12521.; Konstantinides S., Geibel A., Heusel G., et al.; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002 Oct 10; 347(15):1143-50.; Sharifi M., Bay C., Skrocki L., et al.; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol. 2013;111(2):273-7. doi:10.1016/j.amjcard.2012.09.027.; Riva N., Puljak L., Moja L., et al. Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism. J Clin Epidemiol. 2018;97:1-13. doi:10.1016/j.jclinepi.2017.11.012.; Teleb M, Porres-Aguilar M, Anaya-Ayala JE, et al. Potential role of systemic thrombolysis in acute submassive intermediate risk pulmonary embolism: review and future perspectives. Ther Adv Cardiovasc Dis. 2016;10(2):103–110. doi:10.1177/1753944716630694; Meyer G., Vicaut E., Danays T., et al.; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370(15):1402-11. doi:10.1056/NEJMoa1302097.; Miranda CH. Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. J Bras Pneumol. 2019 Feb 11;45(1):e20180297. doi:10.1590/1806-3713/e20180297.; Klok F.A., Dzikowska-Diduch O., Kostrubiec M., et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J. Thromb. Haemost. 2016;14(1):121-8. doi:10.1111/jth.13175; Goldhaber S.Z. PEITHO Long-Term Outcomes Study: Data Disrupt Dogma. J Am Coll Cardiol. 2017 Mar 28;69(12):1545-1548. doi:10.1016/j.jacc.2017.01.027.; Konstantinides S.V., Vicaut E., Danays T., et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol. 2017;69(12):1536-1544. doi:10.1016/j.jacc.2016.12.039.; Jimenez D, de Miguel-Diez J, Guijarro R, et al; RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE Registry. J Am Coll Cardiol. 2016;67(2):162–170 doi:10.1016/j.jacc.2015.10.060.; Wang C, Zhai Z, Yang Y, et al.; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; Feb;137(2):254-62. doi:10.1378/chest.09-0765.; Kiser TH, Burnham EL, Clark B, et al. Half-dose versus full-dose alteplase for treatment of pulmonary embolism. Crit Care Med. 2018 Oct;46(10):1617-1625. doi:10.1097/CCM.0000000000003288.; Jin Q, Luo Q, Zhao Z, et al. Half-dose versus full-dose alteplase therapy in pulmonary embolism: does half dose really lose? Crit Care Med. 2018 Dec;46(12):e1223-e1224. doi:10.1097/CCM.0000000000003384; Rothschild DP, Goldstein JA, Bowers TR. Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: Clinical efficacy but attendant hemorrhagic risks. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):506-510. doi:10.1002/ccd.28042.; Halaby R, Giri J. Keep it simple? Half-dose systemic thrombolysis or catheter-directed thrombolysis for pulmonary embolism. Vasc Med. 2019 Mar 5:1358863X18824653. doi:10.1177/1358863X18824653.; https://www.medarhive.ru/jour/article/view/963Test
الإتاحة: https://doi.org/10.20514/2226-6704-2019-9-5-348-366Test
https://doi.org/10.20514/2226-6704-2019-0-5Test
https://doi.org/10.1093/eurheartj/ehu283Test
https://doi.org/10.1001/jama.2018.14346Test
https://doi.org/10.1016/j.amjmed.2013.02.024Test
https://doi.org/10.1016/j.jacc.2015.11.061Test
https://doi.org/10.1111/j.1538-7836.2010.03938.xTest
https://doi.org/10.20514/22266704-2018-0-5-346-360Test
https://doi.org/10.1093/eurheartj/ehn310Test
https://doi.org/10.1161/CIR.0b013e318214914fTest -
2دورية أكاديمية
المؤلفون: N. T. Vatutin, G. G. Taradin, I. V. Kanisheva, D. V. Bort, A. N. Zagorujko, Н. Т. Ватутин, Г. Г. Тарадин, И. В. Канишева, Д. В. Борт, А. Н. Загоруйко
المصدر: The Russian Archives of Internal Medicine; Том 8, № 5 (2018); 346-360 ; Архивъ внутренней медицины; Том 8, № 5 (2018); 346-360 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2018-8-5
مصطلحات موضوعية: эндоваскулярное лечение, thromboembolism of pulmonary artery, treatment, risk stratification, patient selection, interventional methods, catheter approaches, catheter directed thrombolysis, ultrasound, endovascular treatment, тромбоэмболия легочной артерии, лечение, стратификация риска, отбор пациентов, интервенционные методы, катетерные методики, катетер-управляемый тромболизис, ультразвук
وصف الملف: application/pdf
العلاقة: https://www.medarhive.ru/jour/article/view/836/704Test; https://www.medarhive.ru/jour/article/view/836/724Test; Konstantinides S.V., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) endorsed by the european respiratory society (ERS). European Heart Journal. 2014; 35(43): 3033–69, 3069a-3069k. DOI:10.1093/eurheartj/ehu283.; Konstantinides S.V., Barco S., Lankeit M., et al. J Am Coll Cardiol. 2016; 67(8): 976-90. doi:10.1016/j.jacc.2015.11.061.; Cohen A.T., Agnelli G., Anderson F.A., et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007; 98(4): 756–64.; Raskob G.E., Angchaisuksiri P., Blanco A.N., et al. Thrombosis: a major contributor to global disease burden. Semin. Thromb. Hemost. 2014; 40(07): 724–735.; Turetz M., Sideris A.T., Friedman O.A., et al. Epidemiology, pathophysiology, and natural history of pulmonary embolism. Semin. Intervent. Radiol. 2018; 35(2): 92-98. doi:10.1055/s-0038-1642036.; Jolly M., Phillips J. Pulmonary embolism: current role of catheter treatment options and operative thrombectomy. Surg. Clin. North. Am. 2018; 98(2): 279-292. doi:10.1016/j.suc.2017.11.009.; Zarghouni M., Charles H.W., Maldonado T.S., et al. Catheter-directed interventions for pulmonary embolism. Cardiovasc Diagn Ther. 2016; 6(6): 651-661. doi:10.21037/cdt.2016.11.15.; Jaff M.R., McMurtry M.S., Archer S.L., et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a Scientific Statement from the American Heart Association. Circulation. 2011; 123(16): 1788-830. doi:10.1161/CIR.0b013e318214914f.; Kucher N., Boekstegers P., Muller O.J., et al. Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism. Circulation. 2014; 129(4): 479-86. doi:10.1161/CIRCULATIONAHA.113.005544.; Масленников М.А., Синкевич Н.С., Савченко А.П. Современные эндоваскулярные методики терапии венозных тромбозов и тромбоэмболий. Consilium Medicum. 2015; 17(5): 44–48.; Малышенко Е.С., Попов В.А., Хаес Б.Л. и др. Алгоритм интенсивного лечения острых тромбоэмболий легочной артерии: акцент на инвазивность. Комплексные проблемы сердечно-сосудистых заболеваний. 2015; 1; 71-77.; Jaber W.A., Fong P.P., Weisz G., et al. Acute pulmonary embolism: with an emphasis on an interventional approach. J Am Coll Cardiol. 2016; 67(8): 991-1002. doi:10.1016/j.jacc.2015.12.024.; De Gregorio M.A., Guirola J.A., Lahuerta C., et al. Interventional radiology treatment for pulmonary embolism. World J Radiol. 2017; 9(7): 295-303. doi:10.4329/wjr.v9.i7.295.; Comerota AJ, Throm RC, Mathias SD, et al. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves healthrelated quality of life. J Vasc Surg. 2000; 32: 130-7.; Enden T., Wik H.S., Kvam A.K., et al. Health-related quality of life after catheter-directed thrombolylsis for deep vein thrombosis: secondary outcomes of the randomised, non-blinded, parallel-group CaVenT study. BMJ Open. 2013; 3: e002984.; Huisman M.V., Barco S., Cannegieter S.C., et al. Pulmonary embolism. Nat. Rev. Dis. Primers. 2018; 4: 18028. doi:10.1038/nrdp.2018.28.; Абдульянов И.В., Вагизов И.И., Омеляненко А.С. Современная стратегия лечения острой тромбоэмболии легочной артерии. Практическая медицина. 2015; 2(36): 35-40.; Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999; 353(9162): 1386-1389. doi:10.1016/S0140-6736(98)07534-5.; Kasper W., Konstantinides S., Geibel A., et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol. 1997; 30: 1165–1171.; Кочмарёва Е.А., Кокорин В.А., Волкова А.Л. и др. Предикторы краткосрочных осложнений тромбоэмболии легочной артерии высокого и промежуточного риска. Российский кардиологический журнал. 2017; 9(149): 7–12. doi:10.15829/ 1560-4071-2017-9-7-12.; Aujesky D., Obrosky D.S., Stone R.A., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am. J. Respir. Crit. Care Med. 2005; 172: 1041–1046.; Miller G.A., Sutton G.C., Kerr I.H., et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971; 2: 681– 684.; Jimenez D., Aujesky D., Moores L., et al. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med. 2010; 170: 1383-9. doi:10.1001/archinternmed.2010.199.; Smithburger P.L., Campbell S., Kane-Gill S.L. Alteplase treatment of acute pulmonary embolism in the intensive care unit. Crit Care Nurse. 2013; 33(2): 17-27. doi:10.4037/ccn2013626.; Bhatt A., Al-Hakim R., Benenati J.F. Techniques and devices for catheter directed therapy in pulmonary embolism. Tech Vasc Interv Radiol. 2017; 20(3): 185-192. doi:10.1053/j.tvir.2017.07.008.; Vedantham S., Goldhaber SZ, Julian JA, et al. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med. 2017 Dec 7;377(23):2240-2252. doi:10.1056/NEJMoa1615066.; Chiarello M.A., Sista A.K. Catheter-directed thrombolysis for submassive pulmonary embolism. Semin. Intervent. Radiol. 2018; 35(2): 122-128. doi:10.1055/s-0038-1642041.; Meyer G., Vicaut E., Danays T., et al. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med. 2014; 370(15): 1402-11. doi:10.1056/NEJMoa1302097.; Konstantinides S., Geibel A., Heusel G., et al. Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002; 347(15): 1143-50. 30. Wang T.F., Squizzato A., Dentali F., et al. The role of thrombolytic therapy in pulmonary embolism. Blood. 2015; 125(14): 2191-2199. doi:10.1182/blood-2014-08-559278.; Avgerinos E.D., Saadeddin Z., Abou Ali A.N., et al. A meta-analysis of outcomes of catheter-directed thrombolysis for high- and intermediate-risk pulmonary embolism. J Vasc Surg Venous Lymphat Disord. 2018; 6(4): 530-540. doi:10.1016/j.jvsv.2018.03.010.; Verstraete M., Miller G.A., Bounameaux H., et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation. 1988; 77(2):353-60.; Kuo W.T., Banerjee A., Kim P.S., et al. Pulmonary Embolism Response to Fragmentation, Embolectomy, and Catheter Thrombolysis (PERFECT). Chest. 2015; 148(3): 667-673. doi:10.1378/chest.15-0119.; Engelberger R.P., Moschovitis A., Fahrni J., et al. Fixed low-dose ultrasound-assisted catheter-directed thrombolysis for intermediate and high-risk pulmonary embolism. Eur Heart J. 2015; 36(10): 597604. doi:10.1093/eurheartj/eht531.; Tapson V.F., Sterling K., Jones N., et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: The OPTALYSE PE Trial. JACC Cardiovasc Interv. 2018; 11(14): 1401-1410. doi:10.1016/j. jcin.2018.04.008.; Devcic Z., Kuo W.T. Percutaneous pulmonary embolism thrombectomy and thrombolysis: technical tips and tricks. Semin. Intervent. Radiol. 2018; 35(2): 129-135. doi:10.1055/s-0038-1642042.; Schmitz-Rode T., Janssens U., Duda S.H., et al. Massive pulmonary embolism: percutaneous emergency treatment by pigtail rotation catheter. J Am Coll Cardiol. 2000; 36(2): 375-80.; Piazza G., Hohlfelder B., Jaff M.R., et al. A prospective, single-arm, multicenter trial of ultrasound-facilitated, catheter-directed, low-dose fibrinolysis for acute massive and submassive pulmonary embolism: the SEATTLE II study. JACC Cardiovasc Interv. 2015; 8: 1382-92.; Kuo W.T. Endovascular therapy for acute pulmonary embolism. J Vasc Interv Radiol. 2012; 23(2): 167-79.; Bonvini R.F., Roffi M., Bounameaux H., et al. AngioJet rheolytic thrombectomy in patients presenting with high-risk pulmonary embolism and cardiogenic shock: a feasibility pilot study. EuroIntervention. 2013; 8(12): 1419-27. doi:10.4244/EIJV8I12A215.; Greenfield L.J., Proctor M.C., Williams D.M., et al. Long-term experience with transvenous catheter pulmonary embolectomy. J Vasc Surg. 1993; 18: 450-7.; Bayiz H., Dumantepe M., Teymen B., et al. Percutaneous aspiration thrombectomy in treatment of massive pulmonary embolism. Heart Lung Circ. 2015; 24(1): 46–54. doi:10.1016/j.hlc.2014.06.014.; Enden T., Haig Y., Kløw N.E., et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012; 379(9810): 31-8. doi:10.1016/S01406736(11)61753-4.; Bashir R., Zack C.J., Zhao H., et al. Comparative outcomes of catheterdirected thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med. 2014; 174: 1494-501.; Brailovsky Y., Lakhter V, Zack C., et al. Comparative outcomes of catheter–directed thrombolysis with anticoagulation versus anticoagulation alone in cancer patients with deep venous thrombosis. J Am Coll Cardiol. 2013, 61(10): 932-7. doi:10.1016/S0735-1097(13)62073-2; Brailovsky Y., Zack C., Zhao H., et al. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation versus anticoagulation alone in the treatment of proximal deep vein thrombosis in patients with chronic kidney disease. J Amer Coll Cardiol. 2014, 63(12): 1215-89. DOI:10.1016/S0735-1097(14)62129-X; Jarrett H., Zack C.J., Aggarwal V., et al. Impact of institutional volume on outcomes of catheter directed thrombolysis in the treatment of acute proximal deep vein thrombosis: a 6-year US experience (2005-2010). Circulation. 2015; 132: 1127-35. Doi:10.1161/CIRCULATIONAHA.115.015555.; Vedantham S., Sista A.K., Klein S.J., et al. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2014; 25(9): 1317-25. doi:10.1016/j.jvir.2014.04.019.; https://www.medarhive.ru/jour/article/view/836Test
الإتاحة: https://doi.org/10.20514/2226-6704-2018-0-5-346-360Test
https://doi.org/10.20514/2226-6704-2018-8-5Test
https://doi.org/10.1093/eurheartj/ehu283Test
https://doi.org/10.1016/j.jacc.2015.11.061Test
https://doi.org/10.1055/s-0038-1642036Test
https://doi.org/10.1016/j.suc.2017.11.009Test
https://doi.org/10.21037/cdt.2016.11.15Test
https://doi.org/10.1161/CIR.0b013e318214914fTest
https://doi.org/10.1161/CIRCULATIONAHA.113.005544Test
https://doi.org/10.1016/j.jacc.2015.12.024Test